Dermatology clinical cases and Presidential address

The clinical cases are to gain an understanding of the diagnosis and management of some of the rarer and more unusual dermatology conditions and unusual presentations of common dermatological problems.  

By attending, you will:

• Gain an understanding of the diagnosis and management of some of the rarer and more unusual dermatology conditions and unusual presentations of common dermatological problems   
• Know about recent progress in diagnostics and management of dermatological conditions 
• Understand the impact of skin disorders on individuals and the importance of a holistic approach to management and know about new research in dermatology   

For those attending in person, the clinical cases will be followed by a drinks reception to facilitate networking.

The Hugh Wallace Essay Prize and the Trainee Research Prize will also be presented and awarded at the meeting. Click here to apply and make your submission. For further details on the prize, please see below. 

Book to attend this event in person or virtually. To view the rates and agenda, please select your preference below. 

Attendance criteria

You can only attend this meeting if you hold a Consultant or training post in dermatology. You must bring ID with you to show this. Exceptions are made for those who are Section members (by completing an additional application form) who have made significant contributions to dermatology and are of good standing in the profession.

This event will be recorded* and all registered delegates will be able to access the recording for 60 days after. The link will be distributed 3 days after the event takes place. 

Follow us on: 

Facebook 
Instagram 
LinkedIn 
Twitter 
YouTube 

*Subject to speakers consent

The Dermatology Section would like to thank our Annual Sponsors AbbVie, Almirall, Eucerin, La Roche-Posay & Cerave, Lilly UK, Pfizer and Sanofi for their valued support of the 2023 to 2024 Academic Programme. We would also like to thank our sponsors Aveeno®, Avene, Bristol Myers Squibb and UCB Pharma Ltd for their support of this meeting.
Please note that none of the companies listed has had any influence or involvement over the agenda, content or organisation of the meetings.